At CxT Discovery, we recognized that more than 90% of our proteome has been neglected by the pharma industry. A small proportion linked to economically viable pathologies attracts all the industry’s talent and resources. This has resulted in less than 5% of the human proteome being successfully drugged, with most therapeutic development efforts failing due to a lack of deep scientific knowledge and useful discovery tools.
We are a team of scientists with several decades of biological and drug discovery expertise committing our know-how and creative energy to developing drug candidate molecules in a new way. Our strategy is to interfere with a carefully selected set of neglected proteins identified as likely nodes of cellular regulation to empirically probe their therapeutic utility. By discovering and modulating such nodes, we will interrogate novel intervention points for human pathologies—and not just by ourselves. We will crowdsource the investigation of these compounds’ potential as medicines by providing them to the scientific community.
We realized that the building blocks of our proteome are often similar enough to
compete for common pools of interacting partners. This simple principle could be the basis of a type of competitive egulation, thus far not extensively studied in complex biological systems. CxT aims to uncover these regulatory systems as high-potential targets of our drug development programs.
If cells utilize this form of competitive regulation, where protein domains compete for common partners and resources, then modulating these interactions offers a potential new logic for intervening in cellular regulatory networks. CxT Discovery is currently leveraging deep insights into conserved structural protein domains to identify, and test the function of, such nodes of regulation. By subsequently identifying and optimizing
chemical matter to interfere with these regulatory nodes, CxT will provide the scientific community with new tools to modulate a wide range of cellular functions.
Discovering new regulatory nodes and developing tools to modulate their activity holds great potential for discovering new therapeutics. Target pathologies will be identified by internal research in dialogue with the crowdsourced science facilitated by distributing our small molecule drug candidates to the research community.
Check us out on LinkedIn! or reach out to us directly at info@cxtdiscovery.org
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.